Auto-brewery syndrome (ABS), also termed endogenous ethanol fermentation, is a rare disorder in which ingested carbohydrates are metabolized by gut microorganisms into ethanol (alcohol), leading to clinically apparent intoxication without an external source of alcohol. The core mechanism involves overgrowth and metabolic activity of fermenting organisms—most often certain yeasts such as Saccharomyces species or, less commonly, bacteria—within the gastrointestinal tract. These organisms convert sugars into ethanol and carbon dioxide through fermentation pathways. In most individuals, hepatic and peripheral metabolism rapidly detoxifies small quantities of ethanol; in ABS, either ethanol production is sufficiently high, clearance is impaired, or both, allowing ethanol levels to rise to concentrations that produce neurologic and behavioral signs.
Clinically, ABS can present with recurrent episodes resembling intoxication: slurred speech, ataxia or impaired coordination, sedation, behavioral changes, and impaired judgment. Some patients report blackouts, confusion, dizziness, or headaches temporally associated with high-carbohydrate meals (for example, bread, pasta, fruit, or sugary beverages). A distinctive clue is evidence of ethanol odor (“alcohol breath”) and positive breathalyzer or blood ethanol levels during episodes when the patient reports abstinence from alcohol. Because symptoms overlap with substance use intoxication and some neurologic conditions, ABS is frequently misdiagnosed as alcohol use disorder, intoxication from other sources, seizure disorders, or psychiatric illness until biochemical testing clarifies the pattern.
Diagnostic evaluation generally aims to demonstrate endogenous ethanol production while excluding external ingestion and common medical mimics. A typical approach includes: (1) careful history focusing on time course, dietary triggers, medication or supplement use, and potential access to alcohol-containing products; (2) measurement of blood ethanol concentration and breath alcohol during symptomatic periods; (3) exclusion testing for alcohol exposure sources, including inadvertent intake (e.g., cough syrups, mouthwashes, fermented foods) and workplace exposures; and (4) confirmation via carbohydrate challenge testing under controlled conditions. In supervised carbohydrate challenges, patients ingest a standardized glucose or carbohydrate load while serial blood ethanol (and sometimes breath alcohol) measurements are obtained. Rising ethanol levels following the carbohydrate load support ABS.
Microbiologic and gastrointestinal assessments may include stool culture or molecular testing to identify fermenting organisms, evaluation for dysbiosis, and assessment for predisposing conditions. ABS appears more likely in certain contexts: prior or ongoing antibiotic use that disrupts normal flora; immunologic or metabolic vulnerability; structural gastrointestinal abnormalities such as short bowel syndrome, fistulas, or altered gut motility; and conditions that facilitate microbial overgrowth. There are also reports associating ABS with diabetes mellitus or other states of altered carbohydrate availability, though causality varies by case. Liver disease can worsen susceptibility by reducing ethanol clearance, amplifying symptom severity even if microbial production is moderate.
Treatment focuses on reducing ethanol-producing organisms, limiting fermentable carbohydrate availability, and supporting metabolic clearance. Antimicrobial strategies are individualized based on suspected organism type and culture data. For yeast-predominant cases, antifungal therapy (commonly azoles such as fluconazole) may be used; for bacterial contributions, antibiotics targeting the relevant microbiota may be considered. Because the gut ecosystem is complex, recurrence can occur when dysbiosis persists, so maintenance strategies may include dietary modification and, in selected cases, probiotic or microbiome-directed interventions. Dietary management often involves reducing rapidly fermentable carbohydrates to decrease substrate for fermentation, emphasizing controlled carbohydrate intake rather than total elimination. Patients may also benefit from coordinated care with gastroenterology, infectious disease, and addiction medicine or psychiatry to address safety, stigma, and functional impairment.
Prognosis depends on the underlying driver of dysbiosis and the patient’s response to therapy. Some individuals achieve sustained remission after targeted antimicrobial treatment plus dietary control, while others require prolonged or repeated courses, particularly if predisposing GI or metabolic conditions cannot be corrected. During episodes, safety precautions are important: driving or operating machinery should be avoided, and clinicians should document objective biochemical findings to prevent harmful misattribution to substance misuse.
Given the overlap with other disorders, a structured diagnostic pathway is essential. ABS is not the same as alcohol use disorder, although it can produce identical bedside signs. The distinction hinges on objective ethanol measurements tied to carbohydrate intake and absence of exogenous consumption. Emerging research continues to clarify the microbial ecology, host factors affecting fermentation and clearance, and the best microbiome-modulating strategies. For patients, timely recognition can reduce unnecessary legal and medical harm and enable targeted treatment to prevent recurrent intoxication-like events.
Source: [@RT_com]
RT: Canadian man’s body brews its own alcohol due to ‘auto‑brewery syndrome’ For ten years, Eric Poulin suffered slurred speech, loss of coordination, blackouts, and alcohol breath — without drinking a drop His gut bacteria ferment alcohol faster than his body can break it down. #breaking
— @RT_com May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
